BACKGROUND: Case reports suggest that duloxetine hepatotoxicity may arise, but risk factors, presenting features and clinical course are not well-described. AIM: To describe the presenting features and outcomes of seven well-characterized patients with suspected duloxetine hepatotoxicity. METHODS: Patients enrolled in the Drug-Induced Liver Injury Network Prospective Study underwent an extensive laboratory and clinical evaluation to exclude competing aetiologies of liver injury as well as a standardized assessment for causality and disease severity. RESULTS: Between 1/2006 and 9/2009, six of the seven cases of DILI attributed to duloxetine were assessed as definite or very likely. Median patient age was 49 years, six (86%) were women and the median latency from drug initiation to DILI onset was 50 days. Six patients developed jaundice and the median peak alanine aminotransferase in the five patients with acute hepatocellular injury was 1633 IU/L. Ascites developed in one patient and acute renal dysfunction in two others (29%). All patients recovered without liver transplantation even though three had pre-existing chronic liver disease. Liver histology in four cases demonstrated varying patterns of liver injury. CONCLUSIONS: Duloxetine hepatotoxicity developed within 2 months of drug intake and led to clinically significant liver injury. A spectrum of laboratory, histological and extra-hepatic features were noted at presentation.
BACKGROUND: Case reports suggest that duloxetinehepatotoxicity may arise, but risk factors, presenting features and clinical course are not well-described. AIM: To describe the presenting features and outcomes of seven well-characterized patients with suspected duloxetinehepatotoxicity. METHODS:Patients enrolled in the Drug-Induced Liver Injury Network Prospective Study underwent an extensive laboratory and clinical evaluation to exclude competing aetiologies of liver injury as well as a standardized assessment for causality and disease severity. RESULTS: Between 1/2006 and 9/2009, six of the seven cases of DILI attributed to duloxetine were assessed as definite or very likely. Median patient age was 49 years, six (86%) were women and the median latency from drug initiation to DILI onset was 50 days. Six patients developed jaundice and the median peak alanine aminotransferase in the five patients with acute hepatocellular injury was 1633 IU/L. Ascites developed in one patient and acute renal dysfunction in two others (29%). All patients recovered without liver transplantation even though three had pre-existing chronic liver disease. Liver histology in four cases demonstrated varying patterns of liver injury. CONCLUSIONS:Duloxetinehepatotoxicity developed within 2 months of drug intake and led to clinically significant liver injury. A spectrum of laboratory, histological and extra-hepatic features were noted at presentation.
Authors: Paul E Greenberg; Ronald C Kessler; Howard G Birnbaum; Stephanie A Leong; Sarah W Lowe; Patricia A Berglund; Patricia K Corey-Lisle Journal: J Clin Psychiatry Date: 2003-12 Impact factor: 4.384
Authors: James Gahimer; Joachim Wernicke; Ilker Yalcin; Melissa J Ossanna; Meghan Wulster-Radcliffe; Lars Viktrup Journal: Curr Med Res Opin Date: 2007-01 Impact factor: 2.580
Authors: A James Hanje; Lindsay J Pell; Nicholas A Votolato; Wendy L Frankel; Robert B Kirkpatrick Journal: Clin Gastroenterol Hepatol Date: 2006-06-22 Impact factor: 11.382
Authors: L P James; J T Wilson; R Simar; H C Farrar; G L Kearns; P M Simpson; J A Hinson; N R Pumford Journal: Clin Pediatr (Phila) Date: 2001-05 Impact factor: 1.168
Authors: Don C Rockey; Leonard B Seeff; James Rochon; James Freston; Naga Chalasani; Maurizio Bonacini; Robert J Fontana; Paul H Hayashi Journal: Hepatology Date: 2010-06 Impact factor: 17.425
Authors: L N Bell; R Vuppalanchi; P B Watkins; H L Bonkovsky; J Serrano; R J Fontana; M Wang; J Rochon; N Chalasani Journal: Aliment Pharmacol Ther Date: 2012-03 Impact factor: 8.171
Authors: Melissa A Martinez; Raj Vuppalanchi; Robert J Fontana; Andrew Stolz; David E Kleiner; Paul H Hayashi; Jiezhun Gu; Jay H Hoofnagle; Naga Chalasani Journal: Clin Gastroenterol Hepatol Date: 2014-08-09 Impact factor: 11.382
Authors: David S Goldberg; Kimberly A Forde; Dena M Carbonari; James D Lewis; Kimberly B F Leidl; K Rajender Reddy; Kevin Haynes; Jason Roy; Daohang Sha; Amy R Marks; Jennifer L Schneider; Brian L Strom; Douglas A Corley; Vincent Lo Re Journal: Gastroenterology Date: 2015-02-28 Impact factor: 22.682
Authors: Naga Chalasani; Herbert L Bonkovsky; Robert Fontana; William Lee; Andrew Stolz; Jayant Talwalkar; K Rajendar Reddy; Paul B Watkins; Victor Navarro; Huiman Barnhart; Jiezhun Gu; Jose Serrano Journal: Gastroenterology Date: 2015-03-06 Impact factor: 22.682
Authors: Nancy D Lin; Heather Norman; Arie Regev; David G Perahia; Hu Li; Curtis Liming Chang; David D Dore Journal: BMC Gastroenterol Date: 2015-10-14 Impact factor: 3.067
Authors: Nury M Steuerwald; David M Foureau; H James Norton; Jie Zhou; Judith C Parsons; Naga Chalasani; Robert J Fontana; Paul B Watkins; William M Lee; K Rajender Reddy; Andrew Stolz; Jayant Talwalkar; Timothy Davern; Dhanonjoy Saha; Lauren N Bell; Huiman Barnhart; Jiezhun Gu; Jose Serrano; Herbert L Bonkovsky Journal: PLoS One Date: 2013-12-27 Impact factor: 3.240
Authors: Diogo Telles-Correia; António Barbosa; Helena Cortez-Pinto; Carlos Campos; Nuno B F Rocha; Sérgio Machado Journal: World J Gastrointest Pharmacol Ther Date: 2017-02-06